Basic Information
Cizzle Biotech Focuses on Early Lung Cancer Detection by Developing Immunoassay Tests for the CIZ1 B Biomarker. The core technology of Cizzle Biotech has been patented and a laboratory test has been developed, which has been used to validate the detection of lung cancer using the CIZ1 B biomarker.
Cizzle Biotech, Ltd
London,England,United Kingdom
15~50 people
January 01, 2005
cizzle@investor-focus.co.uk
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios